Bendamustine therapy in chronic lymphocytic leukemia

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Cancer Facts and Figures; 2008
   Google Scholar
• Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995;75(Suppl 1):381-94
   PubMed Web of Science ®Google Scholar
• Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008;19(4):379-90
   PubMed Web of Science ®Google Scholar
• Foon KA. Chronic lymphoid leukemias: recent advances in biology and therapy. Stem Cells 1995;13(1):1-21
   PubMed Web of Science ®Google Scholar
• Arp EW Jr, Wolf PH, Checkoway H. Lymphocytic leukemia and exposures to benzene and other solvents in the rubber industry. J Occup Med 1983;25(8):598-602
   PubMedGoogle Scholar
• Monson RR, Fine LJ. Cancer mortality and morbidity among rubber workers. J Natl Cancer Inst 1978;61(4):1047-53
   PubMed Web of Science ®Google Scholar
• Brown LM, Blair A, Gibson R, et al. Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota. Cancer Res 1990;50(20):6585-91
   PubMed Web of Science ®Google Scholar
• Burmeister LF, Everett GD, Van Lier SF, Isacson P. Selected cancer mortality and farm practices in Iowa. Am J Epidemiol 1983;118(1):72-7
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56
   PubMed Web of Science ®Google Scholar
• Palma M, Kokhaei P, Lundin J, et al. The biology and treatment of chronic lymphocytic leukemia. Ann Oncol 2006;17(Suppl 10):x144-54
   Google Scholar
• Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40(2):855-64
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94(6):1840-7
   PubMed Web of Science ®Google Scholar
• Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116(1):142-50
   PubMed Web of Science ®Google Scholar
• D'Arena G, Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42(1-2):109-14
   PubMed Web of Science ®Google Scholar
• Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101(4):1262-9
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98(1):181-6
   PubMed Web of Science ®Google Scholar
• Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 2007;13(18 Pt 1):5295-304
   PubMed Web of Science ®Google Scholar
• Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17(12):2426-34
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112(5):1923-30
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-54
   PubMed Web of Science ®Google Scholar
• Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2003;88(4):593-8
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99(6):2262-4
   PubMed Web of Science ®Google Scholar
• Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24(6):969-75
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-6
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Bullinger L, Benner A, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia 1999;13(9):1331-4
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89(7):2516-22
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85(6):1580-9
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25(34):5448-57
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109(2):399-404
   PubMed Web of Science ®Google Scholar
• Wierda WG. Current and investigational therapies for patients with CLL. Hematology / the Education Program of the American Society of Hematology. Am Soc Hematol 2006;285-94
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien SM. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol 2006;33(2):202-9
   PubMed Web of Science ®Google Scholar
• Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999;91(10):861-8
   PubMed Web of Science ®Google Scholar
• Cheson BD. What is new in lymphoma? CA Cancer J Clin 2004;54(5):260-72
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352(8):804-15
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14(1):309-17
   PubMed Web of Science ®Google Scholar
• Kalaycio M. Bendamustine: a new look at an old drug. Cancer 2009;115(3):473-9
   PubMed Web of Science ®Google Scholar
• Konstantinov SM, Kostovski A, Topashka-Ancheva M, et al. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002;128(5):271-8
   PubMed Web of Science ®Google Scholar
• Schwanen C, Hecker T, Hubinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002;16(10):2096-105
   PubMed Web of Science ®Google Scholar
• Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochimica et biophysica acta 1972;287(3):386-9
   PubMed Web of Science ®Google Scholar
• Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002;29(4 Suppl 13):4-11
   PubMed Web of Science ®Google Scholar
• Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti Cancer Drugs 1996;7(4):415-21
   PubMed Web of Science ®Google Scholar
• Roue G, Lopez-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008;14(21):6907-15
   PubMed Web of Science ®Google Scholar
• Marumoto T, Honda S, Hara T, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278(51):51786-95
   PubMed Web of Science ®Google Scholar
• Liu X, Erikson RL. Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle 2003;2(5):424-5
   PubMed Web of Science ®Google Scholar
• Treanda Prescribing Information. Frazer, PA: Cephalon, Inc. 2008
   Google Scholar
• Preiss R, Sohr R, Matthias M, et al. The pharmacokinetics of bendamustine (Cytostasane) in humans. Pharmazie 1985;40(11):782-4
   PubMed Web of Science ®Google Scholar
• Bezek S, Scasnar V, Trnovec T, Grupe R. Hepatobiliary elimination of bendamustin (Cytostasan) in rats. Pharmazie 1991;46(11):810-1
   PubMed Web of Science ®Google Scholar
• Weber H, Amlacher R, Preiss R, Hoffmann H. Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice. Pharmazie 1991;46(8):589-91
   PubMed Web of Science ®Google Scholar
• Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005;33(7):984-92
   PubMed Web of Science ®Google Scholar
• Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007;59(6):759-70
   PubMed Web of Science ®Google Scholar
• Teichert J, Sohr R, Hennig L, et al. Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. Drug Metab Dispos 2009;37(2):292-301
   PubMed Web of Science ®Google Scholar
• Schoppmeyer K, Kreth F, Wiedmann M, et al. A pilot study of bendamustine in advanced bile duct cancer. Anti Cancer Drugs 2007;18(6):697-702
   PubMed Web of Science ®Google Scholar
• Preiss R, Teichert J, Seidel A, et al. Pharmacokinetics and toxicity profile of bendamustine in myeloma patients with end-stage renal disease. Onkologie 2003;26(Suppl 131):717
   Google Scholar
• Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001;127(1):48-54
   PubMed Web of Science ®Google Scholar
• Aivado M, Schulte K, Henze L, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002;29(4 Suppl 13):19-22
   PubMed Web of Science ®Google Scholar
• Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90(10):1357-64
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132(2):99-104
   PubMed Web of Science ®Google Scholar
• Knauf W, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an International Phase III Study. Blood (ASH Aanual Meeting Abstracts) 2007;110(11):2043
   Google Scholar
• Knauf W, Lissitchkov T, Aldaoud A, et al. Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: an updated analysis from an International Phase III Study. Blood 2008;112(11):2091
   Google Scholar
• Niederle N, Balleisen W, Heit W, et al. Eimermacher. Bendamustine vs fludarabine as second line treamtne for patients with chronic lymphocytic leukemi-first interim results of a randomized study. Ann Oncol 2008;19(Suppl 4):379
   Web of Science ®Google Scholar
• Fischer K, Stilgenbauer S, Schweighofer C, et al. Bendamustine in combination with Rituximab (BR) for patients with relapsed Chronic Lymphocytic Leukemia (CLL): a multicenter Phase II Trial of the German CLL study group (GCLLSC). Blood 2007;110(11):3106
   Google Scholar
• Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone–a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 2004;45(5):911-3
   PubMed Web of Science ®Google Scholar
• Rigacci L, Puccini B, Bosi A, et al. Safety and efficacy of bendamustine with or without Rituximab in the treatment of heavily pretreated patients with haematological malignancies: a Multicenter Retrospective Study. Blood 2008;112(11):4945
   Google Scholar
• Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;45(12):2445-9
   PubMed Web of Science ®Google Scholar
• Kahl B, Bartlett N, Leonard J, et al. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-hodgkin lymphoma [abstract 1351]. Blood 2007;110(11)
   PubMedGoogle Scholar
• Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001;86(5):485-93
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26(2):204-10
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(27):4473-9
   PubMed Web of Science ®Google Scholar
• Rummel M, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first line treamtnet of patients with indolent and mantle cell lymphomas-first interim results of a randomized phase III study of the Stil (Study Group Indolent Lymphomas, Germany). Blood 2007;110(11):385
   Google Scholar